

Xdemvy (lotilaner) ophthalmic solution
Effective 04/01/2026

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Medical Benefit	Phone: 833-895-2611	Fax: 888-656-6671
	Pharmacy Benefit	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Xdemvy (lotilaner) ophthalmic solution is indicated for the treatment of Demodex blepharitis.

Coverage Guidelines

If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted when all of the following criteria are met:

1. Member has a diagnosis of Demodex blepharitis.
2. Member exhibits ONE of the following signs of Demodex infestation:
 - a. Collarettes
 - b. Eyelid margin erythema
 - c. Eyelash anomalies (e.g., eyelash misdirection)
3. The requested medication is prescribed by or in consultation with one of the following:
 - a. Ophthalmologist
 - b. Optometrist

Limitations

1. Approvals will be granted for 2 months.

References

1. Rhee, M., Yeu, E., Barnett., M., et al. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351901/>. Accessed October 26, 2023.
2. Xdemvy (lotilaner) [prescribing Information]. Tarsus Pharmaceuticals, Inc. Irvine, CA. July 2023.

Review History

12/13/2023 - Created for December P&T; Effective 2/1/2024.

02/11/2026 – Reviewed and updated at February P&T. Removed requirements that the member try and fail tea tree oil and that the member is experiencing symptoms or architectural changes. Effective 04/01/2026.